Lumber Soars to Six-Month High as Buyers Scurry to Find Wood
0 comments
Benzinga
Eli Lilly Pens $1.5B Pact With Regor For Metabolic Disease Therapies
Eli Lilly And Co (NYSE: LLY) is making a .5 billion biobucks bet on Chinese biotech Regor Therapeutics to develop new therapies for metabolic disorders. Under the deal, Lilly will have a license to select Regor IP with an option to extend the license. Lilly will be responsible for clinical development, manufacturing, and commercialization worldwide except China, Macau, Hong Kong, and Taiwan, where Regor will maintain these rights and responsibilities. Regor will receive an upfront payment of up